title: Cerebellar cognitive affective syndrome associated with topiramate.
abstract: The cerebellar cognitive affective syndrome (CCAS) represents a spectrum of cerebellar-induced neurocognitive and affective disturbances. In this report a patient is described who developed CCAS under a treatment with standard daily dose of the anti-epileptic drug topiramate (TPM). Cognitive disturbances consisted of impaired visuo-spatial memory, concentration deficits and executive dysfunctions. Behavior and affect were characterized by marked mood-swings and several disinhibited symptoms. After a gradual discontinuation of treatment with topiramate, a complete remission of the cognitive and affective symptoms was observed within 6 weeks. Functional neuroimaging studies by means of SPECT were conducted 2 weeks and 8 months following TPM discontinuation. This case report seems to suggest that functional disruption of the cerebello-cerebral circuitry, leading to CCAS, can follow treatment with topiramate.
authors.affiliation: Department of Linguistics, Vrije Universiteit Brussel, Brussels, Belgium.
authors.forename: Hanne
authors.initials: H
authors.lastname: Baillieux
authors.forename: Werner
authors.initials: W
authors.lastname: Verslegers
authors.forename: Philippe
authors.initials: P
authors.lastname: Paquier
authors.forename: Peter P
authors.initials: PP
authors.lastname: De Deyn
authors.forename: Peter
authors.initials: P
authors.lastname: Mariën
mesh_terms: D000588:Amines / Q000008:administration & dosage; D000927:Anticonvulsants / Q000008:administration & dosage / Q000009:adverse effects*; D002220:Carbamazepine / Q000008:administration & dosage / Q000031:analogs & derivatives; D002526:Cerebellar Diseases / Q000139:chemically induced* / Q000150:complications; D002531:Cerebellum / Q000187:drug effects; D003072:Cognition Disorders / Q000139:chemically induced* / Q000150:complications; D003509:Cyclohexanecarboxylic Acids / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D004827:Epilepsy / Q000150:complications / Q000188:drug therapy; D005260:Female; D005500:Follow-Up Studies; D005632:Fructose / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D000077206:Gabapentin; D006801:Humans; D008875:Middle Aged; D019964:Mood Disorders / Q000139:chemically induced* / Q000150:complications; D009483:Neuropsychological Tests; D000078330:Oxcarbazepine; D013577:Syndrome; D000077236:Topiramate; D016896:Treatment Outcome; D005680:gamma-Aminobutyric Acid / Q000008:administration & dosage
chemical_list: D000588:Amines; D000927:Anticonvulsants; D003509:Cyclohexanecarboxylic Acids; D000077236:Topiramate; D005632:Fructose; D002220:Carbamazepine; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D000078330:Oxcarbazepine